Pfizer’s subsidiary Biohaven has agreed to a settlement nearing $60 million to resolve allegations of false claims related to ...

Like many pharma companies, Pfizer is attempting to eat into the sales of rivals with biosimilars – cheaper near copies of biological drugs that have begun to dominate the prescription medicines ...

Pfizer has ventured into the oncology biosimilars space and markets six biosimilars for cancer. Pfizer also advanced its oncology clinical pipeline in 2024, with several candidates entering late ...

Revenues from oncology biosimilars were $285 million, down 7% year over year. Pfizer raised its revenue and earnings guidance for 2024 for the second time this year. Adjusted earnings are expected ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE ... concerns include competition from generic drugs and biosimilars and the looming patent cliff, with over $300 billion ...